What's Going On With Hims & Hers Health Stock Monday?
What's Going On With Hims & Hers Health Stock Monday?
Last quarter, the company easily beat estimates as revenue increased 52% year-over-year and subscribers jumped 43% to 1.9 million. Hims & Hers Health (NYSE:HIMS) shares are moving higher Monday ahead of earnings after the bell. Here's what you need to know before the report.
Hims & Hers Health（紐交所：HIMS）股價在週一盤後報告公佈前上漲。在報告發布前，以下是您需要了解的事項。
What To Know: Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million, according to estimates from Benzinga Pro.
需要了解的內容：Hims & Hers Health將在週一收盤後發佈第三季度業績。根據彭博社Pro的估計，分析師預計該公司每股盈利爲4美分，營業收入爲38220萬美元。
Hims & Hers Health has exceeded analyst estimates on the top and bottom lines in three consecutive quarters heading into Monday's print.
Hims & Hers Health在連續三個季度中均超過分析師的市場預期。
Last quarter, the company easily beat estimates as revenue increased 52% year-over-year and subscribers jumped 43% to 1.9 million.
上一季度，該公司輕鬆超過市場預期，營業收入同比增長52%，訂閱用戶數增長43%，達到190萬。
Hims & Hers Health guided for third-quarter revenue of $375 million to $380 million and raised guidance for the full year from a range of $1.2 billion to $1.23 billion to a new range of $1.37 billion to $1.4 billion.
Hims & Hers Health預計第三季度營業收入爲37500萬美元至38000萬美元，並將全年指導範圍從12億美元至12.3億美元調高至新的區間，即13.7億美元至14億美元。
"An approach to democratizing access to high-quality personalized solutions on our platform at an affordable price continues to resonate with consumers. We are seeing this improve our ability to attract new users to longer-tenured specialties, while also allowing us to more rapidly scale new specialties," CFO Yemi Okupe said in the earnings release.
「我們致力於以平價的高質量個性化解決方案賦能的方式，持續受到消費者青睞。我們看到這一舉措提升了吸引新用戶進入長期專業領域的能力，同時也讓我們更快速地擴展新專業領域，」首席財務官耶米·奧庫佩在業績中表示。
Hims & Hers Health shares are up approximately 135% year-to-date heading into the print. The stock really took off in May after the company announced it would begin selling compounded versions of GLP-1 injections.
Hims & Hers Health股價截至目前年初已上漲約135%，這支股票在五月份宣佈將開始銷售GLP-1注射劑混合版本後真正起飛。
Hims and Hers Health shares experienced increased volatility last month after the FDA removed Eli Lilly And Co's (NYSE:LLY) Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound from its shortage list. Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.
Hims and Hers Health股價在上月經歷了增加的波動性，原因是FDA將禮來（紐交所：LLY）旗下用於治療糖尿病的Mounjaro和減肥藥Zepbound從其短缺清單中移除。Mounjaro自2022年底以來一直在監管機構的短缺清單上，而Zepbound自四月份起就在清單上。
Novo Nordisk's (NYSE:NVO) diabetes drug Ozempic and weight-loss drug Wegovy were also removed from the FDA's shortage list last week.
諾和諾德（NYSE:NVO）的糖尿病藥物奧澤普和減肥藥物威葛唯也於上週從FDA的短缺清單中移除。
Hims & Hers Health sells cheaper versions of Eli Lilly and Novo Nordisk's drugs, known as compounded drugs. Investors and analysts will be looking for updates in the third-quarter report on how the company expects recent FDA shortage changes to impact the company's sales moving forward.
Hims & Hers Health銷售Eli Lilly和Novo Nordisk藥物的廉價版本，稱爲混合藥物。投資者和分析師將在第三季度報告中尋找關於公司如何預計近期FDA短缺變化將如何影響公司銷售的更新。
HIMS Price Action: Hims & Hers Health shares were up 3.93% at $21.16 at the time of publication, according to Benzinga Pro.
HIMS價格走勢：Hims & Hers Health股價在出版時上漲了3.93%，達到21.16美元，據Benzinga Pro報道。
Photo: Shutterstock.
照片：shutterstock。
譯文內容由第三人軟體翻譯。
